Cargando…

Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study

The phosphatidylinositol‐3‐kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is frequently activated in HER2‐negative breast cancer and may play a role in taxane resistance. The phase IB/II TAKTIC trial (NCT01980277) has shown that combining a dual AKT and p70 ribosomal protein S6 kinas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sabatier, Renaud, Vicier, Cécile, Garnier, Séverine, Guille, Arnaud, Carbuccia, Nadine, Isambert, Nicolas, Dalenc, Florence, Robert, Marie, Levy, Christelle, Pakradouni, Jihane, Adelaïde, José, Chaffanet, Max, Sfumato, Patrick, Mamessier, Emilie, Bertucci, François, Goncalves, Anthony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120890/ https://www.ncbi.nlm.nih.gov/pubmed/35122700 http://dx.doi.org/10.1002/1878-0261.13188

Ejemplares similares

Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial
por: Sabatier, Renaud, et al.
Publicado: (2022)

Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial
por: Billon, Emilien, et al.
Publicado: (2022)

Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial
por: Bertucci, François, et al.
Publicado: (2021)

Comparative genomic analysis of primary tumors and metastases in breast cancer
por: Bertucci, François, et al.
Publicado: (2016)

A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases
por: Tyran, Marguerite, et al.
Publicado: (2019)

Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization
por: Sabatier, Renaud, et al.
Publicado: (2014)

Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients
por: Lopresti, Alexia, et al.
Publicado: (2022)

Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification
por: Cervera, N, et al.
Publicado: (2017)

Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy
por: Neron, Mathias, et al.
Publicado: (2022)

Down-Regulation of ECRG4, a Candidate Tumor Suppressor Gene, in Human Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2011)

Prognostic and predictive value of PDL1 expression in breast cancer
por: Sabatier, Renaud, et al.
Publicado: (2014)

Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia
por: Collette, Y, et al.
Publicado: (2015)

NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non‐inflammatory breast cancers
por: Bertucci, François, et al.
Publicado: (2020)

A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study
por: Collignon, A., et al.
Publicado: (2020)

Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study
por: Gonçalves, Anthony, et al.
Publicado: (2016)

Integrated Genomic Analysis of Breast Cancers
por: Addou-Klouche, L, et al.
Publicado: (2012)

New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?
por: Mezni, Essia, et al.
Publicado: (2020)

“Stealth” tumors: Breast cancer cells shun NK-cells anti-tumor immunity
por: Mamessier, Emilie, et al.
Publicado: (2012)

Candidate Luminal B Breast Cancer Genes Identified by Genome, Gene Expression and DNA Methylation Profiling
por: Cornen, Stéphanie, et al.
Publicado: (2014)

Case Report: Two Cases of Metastatic Pancreatoblastoma in Adults: Efficacy of Folfirinox and Implication of the Wnt/β-Catenin Pathway in Genomic Analysis
por: Raoul, Jean-Luc, et al.
Publicado: (2021)

ZNF703 mRNA-Targeting Antisense Oligonucleotide Blocks Cell Proliferation and Induces Apoptosis in Breast Cancer Cell Lines
por: Udu-Ituma, Sandra, et al.
Publicado: (2023)

Signaling pathway switch in breast cancer
por: Guille, Arnaud, et al.
Publicado: (2013)

Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network
por: Nigon, Elsa, et al.
Publicado: (2023)

Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease
por: Mari, Roxane, et al.
Publicado: (2019)

Listeria monocytogenes infection enhances the interaction between rat non-classical MHC-Ib molecule and Ly49 receptors
por: Shegarfi, Hamid, et al.
Publicado: (2018)

Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Sweeney, Christopher J., et al.
Publicado: (2022)

Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms
por: Brecqueville, M, et al.
Publicado: (2011)

PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer
por: Bertucci, Alexandre, et al.
Publicado: (2020)

The Psychological Distress of Cancer Patients following the COVID-19 Pandemic First Lockdown: Results from a Large French Survey
por: Marino, Patricia, et al.
Publicado: (2022)

Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome
por: Luo, Linlin, et al.
Publicado: (2016)

Kinome expression profiling and prognosis of basal breast cancers
por: Sabatier, Renaud, et al.
Publicado: (2011)

Developmental and communicative interrelations of Ly123 and Ly1 cell sets
Publicado: (1980)

TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers
por: de Nonneville, Alexandre, et al.
Publicado: (2019)

Neces-SARI-ly?
por: Martin-Loeches, Ignacio, et al.
Publicado: (2016)

Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2019)

Sacituzumab govitecan in triple-negative breast cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer
por: Bertucci, François, et al.
Publicado: (2023)

The MonarchE trial: improving the clinical outcome in HR(+)/HER2(−) early breast cancer: recent results and next steps
por: Bertucci, François, et al.
Publicado: (2023)

MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors
por: Vicier, C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1i7c8o6ue2cnirc3lolcjj1f5k